Xolair
Author: Chris Mulligan
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Xolair (omalizumab; Roche/Novartis) is a recombinant humanized monoclonal antibody for the treatment of moderate to severe persistent allergic asthma. The drug inhibits the binding of immunoglobulin E (IgE) antibodies to the high affinity IgE receptors present on the surface of mast cells and basophils, thereby minimizing the allergic response. Xolair is available for subcutaneous administration.
TABLE OF CONTENTS
4 Product Profiles
4 Xolair : Asthma
LIST OF FIGURES
11 Figure 1: Asthma – current and future market dynamics analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Xolair in asthma
13 Figure 2: Datamonitor Healthcare’s assessment summary of key marketed and pipeline drugs for asthma
16 Figure 3: Asthma sales across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
4 Table 1: Xolair drug profile
6 Table 2: Xolair pivotal trial data in asthma
10 Table 3: Xolair late-phase trial data in asthma
17 Table 4: Xolair sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
QVM149 
Sign up to the